Skyhawk Therapeutics Expands its Agreement with Merck to Develop Novel Small Molecules Modulating RNA Splicing

Shots:

• Skyhawk will deploy its SkySTARTM platform to develop drug candidates targeting autoimmune and metabolic diseases and will receive an up front $600M/target while Merck get an option to exclusively license WW IP rights to candidates, discovered and developed under the agreement
• If Merck exercises its option, Skyhawk will receive an option fees, milestones and royalties on sales of approved products resulting from the collaboration while Merck will be responsible for development & commercialization. The collaboration now covers neurodegeneration, oncology, autoimmunity, and metabolic diseases
• The expanded collaboration in autoimmune and metabolic diseases reflects SkySTARTM platform’s ability to advance small molecules, addressing the unmet medical needs of patients

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Skyhawk